MODULATION OF MYOFIBER REPAIR BY ANTI-MYOSTATIN STRATEGIES AND/OR PPAR GAMMA LIGANDS, ALONE OR IN COMBINATION WITH STEM CELLS, FOR THE THERAPY OF CRITICAL LIMB ISCHEMIA AND OTHER ISCHEMIC PROCESSES AFFECTING THE SKELETAL MUSCLE
Treating or inhibiting an ischemic condition affecting the skeletal muscle comprising administering an agent having a property to inhibit an activity or a protein expression of myostatin or growth differentiation factor 8 (GDF-8) according to a regimen to treat or inhibit the ischemic condition. Treating or inhibiting an ischemic condition affecting the skeletal muscle including administering an effective amount of a thiazolidenedione or other PPAR gamma agonist at a dosage that do not exert glycemic control or induce overweight. A kit for use in treating or inhibiting an ischemic condition affecting the skeletal muscle comprising a quantity of an agent having a property to inhibit an activity or a protein expression of myostatin or growth differentiation factor 8 (GDF-8) and/or a quantity of a thiazolidenedione or other PPAR gamma agonist and instructions for administration of a dosage of that quantity according to a long term continuous regimen.
